The same molecular playbook that taught our cells to fight a pandemic is now being tested against snake venom that melts human muscle. In a new preclinical study in Trends in Biotechnology, scientists from the University of Reading and the Technical University of Denmark report that intramuscular delivery of mRNA wrapped in lipid nanoparticles can prompt muscle cells to make their own venom blocking antibodies and blunt tissue damage from a notorious viper toxin. The work does not replace traditional antivenom, but it nudges snakebite treatment into the era of genetic instructions rather than bottled animal plasma.
Snakebites are a quiet global disaster, with an estimated 5.4 million people bitten each year, around 140,000 deaths, and 400,000 permanent disabilities. Conventional antivenoms save lives by soaking up toxins circulating in the blood, yet they do relatively little to prevent the brutal local damage around the bite, where venom dismantles muscle fibers, basement membranes, and blood vessels. The team wanted to know whether mRNA technology, the same basic platform used in COVID 19 vaccines, could give those vulnerable tissues a local shield.
Teaching Muscle Cells To Make Their Own Antivenom
The researchers focused on myotoxin II, or M II, a phospholipase A2 like component of Bothrops asper venom that is infamous for destroying skeletal muscle. Instead of manufacturing protein antivenom in animals or bioreactors, they encoded a single chain variable fragment (scFv) antibody against M II in an mRNA construct and packaged it in lipid nanoparticles similar to those in Moderna’s SpikeVax formulation.
In cultured human AB1190 myotubes, a model of mature muscle fibers, the mRNA lipid nanoparticles were taken up without altering cell morphology at appropriate doses. Within 24 hours, the myotubes began secreting M II specific scFvs into the culture medium. When the cells were challenged with either purified M II or whole B. asper venom, untreated cultures lost most of their myosin heavy chain positive area and released high levels of damage enzymes such as creatine kinase and lactate dehydrogenase. In contrast, cells pretreated with M II targeted mRNA displayed far more intact myotube coverage and markedly lower biomarker release.
“For the first time, we’ve shown that mRNA technology can protect muscle tissue from snake venom induced damage. This opens a completely new door for treating snakebites, particularly the local injuries that current antivenoms struggle to prevent.”
Specificity mattered. Myotubes transfected with mRNA encoding antibodies against an unrelated neurotoxin, or exposed to empty lipid nanoparticles, gained no protection. The benefits also depended on dose and timing. At low and intermediate mRNA concentrations, scFv expression rose and muscle protection improved, but at the highest tested dose, the delivery system itself became toxic, shrinking myotube area and spiking LDH and creatine kinase even before venom exposure. And protection did not appear immediately: the cultures needed roughly 12 hours of lead time for M II and closer to 24 hours for whole venom before the antibody levels were high enough to blunt damage.
From Culture Dish To Mouse Muscle
To move beyond the dish, the team injected the mRNA lipid nanoparticles directly into the tibialis anterior muscle of mice. A single intramuscular dose on day 0 produced circulating scFvs within 48 hours. On day 2, the researchers injected M II into the same muscle, then collected tissue and blood a day later.
Mice that received toxin alone showed classic signs of venom induced myopathy: swollen muscles, elevated serum creatine kinase and lactate dehydrogenase, large necrotic areas on haematoxylin and eosin staining, and many fibers infiltrated by IgG, a marker of membrane breach. Basement membrane proteins such as laminin and collagen IV appeared patchy and discontinuous, and the vascular marker CD31 was irregular, accompanied by widespread fibrinogen deposits that signal bleeding and thrombi.
Animals pretreated with M II specific mRNA told a different story. Serum damage markers were significantly lower, muscle weights were closer to controls, and histology showed smaller necrotic areas and fewer IgG positive fibers. Laminin and collagen IV formed more uniform, continuous rings around fibers, suggesting a preserved extracellular matrix scaffold. CD31 staining looked more orderly, while fibrinogen occupied a much smaller area. As in the cell culture experiments, mRNA constructs directed against unrelated toxins failed to protect, underscoring that the effect depends on precise antigen targeting.
Promise, Limits, And The Road To The Field
Despite its striking results, the approach is far from ready to replace glass vials of antivenom in rural clinics. In the study’s models, the mRNA had to be in place before venom exposure to be effective, which is the opposite of real snakebite scenarios where treatment comes after the fact. The technology currently neutralises a single myotoxin from one species, while real world venoms are complex cocktails of many toxin families that act alone and in synergy.
The authors also flag practical hurdles. Manufacturing costs, thermostability, and the logistics of storing mRNA formulations in remote settings all need work, as does reducing the time between injection and protective antibody levels. In addition, fully differentiated human myotubes proved sensitive to high lipid nanoparticle loads, hinting at a narrow therapeutic window that will need careful tuning in any future human application.
Still, the concept of combining classic antivenoms that sweep toxins from the bloodstream with local, mRNA driven antibody production at the bite site is powerful. Conventional plasma derived immunoglobulins often struggle to reach tissue bound venom components, while mRNA constructs could, in theory, sustain antibody expression in exactly those hard to reach zones for days.
As senior author Professor Sakthi Vaiyapuri puts it, “We now need to expand this approach to target multiple venom toxins and solve storage challenges for rural areas, as well as ensure faster production of antibodies in tissues. The potential to reduce disabilities among snakebite victims is significant.”
For now, the study sits at a technology readiness level of 4, a carefully described proof of concept in cells and mice. Yet it suggests a future in which a snakebite kit might one day include not only a cold box of antivenom but also a syringe of genetic instructions, telling injured muscle to help defend itself against the venom that is trying to tear it apart.
Trends in Biotechnology, DOI: 10.1016/j.tibtech.2025.10.017
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.